This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog highlights Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs
by Zacks Equity Research
Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs are part of the Zacks top Analyst Blog .
5 Big Winners as Dollar Strengthens on Fed Rate Hike
by Tirthankar Chakraborty
A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.
5 Winning Stocks Backed by the Overlooked Trick of Rising P/E
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI).
LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
LogicBio Therapeutics (LOGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 123.61% and 129.68%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will LogicBio Therapeutics (LOGC) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
LogicBio Therapeutics (LOGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LogicBio Therapeutics (LOGC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
LogicBio Therapeutics (LOGC) delivered earnings and revenue surprises of -32.00% and -83.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Bet on 5 Top Stocks With Rising P/E for Spectacular Returns
by Sanghamitra Saha
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
LogicBio Therapeutics (LOGC) Jumps: Stock Rises 6.1%
by Zacks Equity Research
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
LogicBio Therapeutics (LOGC) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.